KMS Medisurgi Ltd reported a dip in FY26 performance, with revenue falling 12.4% to Rs 12.21 crore and PAT sliding to Rs 0.25 crore. The company faces a qualified audit opinion over inventory records and gratuity accounting practices. While management plans to enter automotive and electrical adhesive markets, investors should monitor the ongoing inventory reconciliation process and leadership transitions ahead of the AGM on September 30.
KMS Medisurgi FY26 Results and Audit Qualification
Revenue of Rs 12.21 crore; Profit After Tax of Rs 0.25 crore.
Reader Takeaway: Management targets growth via new adhesive product lines, though auditor qualifications on inventory and accounting remain key concerns.
What just happened
KMS Medisurgi Ltd has released its financial results for the year ended March 31, 2026, showing a contraction across key metrics. Revenue declined by roughly 12.42% year-on-year to Rs 12.21 crore, compared to Rs 13.94 crore in the previous year. Profit After Tax also saw a significant drop, falling to Rs 0.25 crore from Rs 0.44 crore in FY25.
Auditor's Qualified Opinion
The company's statutory auditor, M/s H.H. Dedhia & Associates, has issued a qualified opinion on the financial statements. Two primary issues were cited: first, the company's reliance on a group gratuity report from LIC rather than an independent actuarial valuation, which deviates from AS-15 standards. Second, the auditor noted that quantitative stock records were only initiated in FY25 and remain under reconciliation, leaving the auditor unable to verify the closing stock value of Rs 2.54 crore.
Business Strategy
To counteract the recent slowdown, the company plans to diversify its portfolio by introducing a new line of adhesive tapes tailored for automotive and electrical applications. Management believes this shift will support future revenue and profit expansion.
Corporate Developments
The Board has recommended a final dividend of Rs 0.05 per equity share. The 28th Annual General Meeting is set for September 30, 2026. Additionally, the company has appointed Mrs. Pooja Soni as Company Secretary and Compliance Officer, and Mr. Rohan Devang Kanakia is seeking re-appointment as a director.
What to track next
Investors should closely follow the progress of the inventory reconciliation process and the market reception to the company’s new product segment. Continued transparency regarding the auditor's concerns on accounting standards will be critical for shareholder confidence.